S&P 500   3,244.67 (-2.79%)
DOW   28,135.44 (-2.96%)
QQQ   222.48 (-3.38%)
AAPL   299.54 (-4.32%)
FB   200.89 (-4.42%)
MSFT   172.47 (-3.43%)
GOOGL   1,424.47 (-3.98%)
AMZN   2,002.89 (-4.44%)
CGC   20.90 (-4.48%)
NVDA   277.89 (-5.50%)
BABA   205.42 (-3.38%)
MU   54.68 (-4.05%)
GE   11.91 (-2.78%)
TSLA   843.04 (-6.43%)
AMD   49.75 (-6.63%)
ACB   1.59 (-4.80%)
F   7.64 (-3.17%)
BAC   32.94 (-4.13%)
DIS   132.35 (-4.76%)
GILD   72.85 (+4.52%)
S&P 500   3,244.67 (-2.79%)
DOW   28,135.44 (-2.96%)
QQQ   222.48 (-3.38%)
AAPL   299.54 (-4.32%)
FB   200.89 (-4.42%)
MSFT   172.47 (-3.43%)
GOOGL   1,424.47 (-3.98%)
AMZN   2,002.89 (-4.44%)
CGC   20.90 (-4.48%)
NVDA   277.89 (-5.50%)
BABA   205.42 (-3.38%)
MU   54.68 (-4.05%)
GE   11.91 (-2.78%)
TSLA   843.04 (-6.43%)
AMD   49.75 (-6.63%)
ACB   1.59 (-4.80%)
F   7.64 (-3.17%)
BAC   32.94 (-4.13%)
DIS   132.35 (-4.76%)
GILD   72.85 (+4.52%)
S&P 500   3,244.67 (-2.79%)
DOW   28,135.44 (-2.96%)
QQQ   222.48 (-3.38%)
AAPL   299.54 (-4.32%)
FB   200.89 (-4.42%)
MSFT   172.47 (-3.43%)
GOOGL   1,424.47 (-3.98%)
AMZN   2,002.89 (-4.44%)
CGC   20.90 (-4.48%)
NVDA   277.89 (-5.50%)
BABA   205.42 (-3.38%)
MU   54.68 (-4.05%)
GE   11.91 (-2.78%)
TSLA   843.04 (-6.43%)
AMD   49.75 (-6.63%)
ACB   1.59 (-4.80%)
F   7.64 (-3.17%)
BAC   32.94 (-4.13%)
DIS   132.35 (-4.76%)
GILD   72.85 (+4.52%)
S&P 500   3,244.67 (-2.79%)
DOW   28,135.44 (-2.96%)
QQQ   222.48 (-3.38%)
AAPL   299.54 (-4.32%)
FB   200.89 (-4.42%)
MSFT   172.47 (-3.43%)
GOOGL   1,424.47 (-3.98%)
AMZN   2,002.89 (-4.44%)
CGC   20.90 (-4.48%)
NVDA   277.89 (-5.50%)
BABA   205.42 (-3.38%)
MU   54.68 (-4.05%)
GE   11.91 (-2.78%)
TSLA   843.04 (-6.43%)
AMD   49.75 (-6.63%)
ACB   1.59 (-4.80%)
F   7.64 (-3.17%)
BAC   32.94 (-4.13%)
DIS   132.35 (-4.76%)
GILD   72.85 (+4.52%)
Log in

Arbutus Biopharma News Headlines (NASDAQ:ABUS)

$2.92
-0.33 (-10.15 %)
(As of 02/24/2020 11:12 AM ET)
Today's Range
$2.79
Now: $2.92
$3.03
50-Day Range
$2.59
MA: $3.06
$3.42
52-Week Range
$0.82
Now: $2.92
$4.75
Volume12,052 shs
Average Volume757,185 shs
Market Capitalization$181.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45

Headlines

Arbutus Biopharma (NASDAQ ABUS) News Headlines

Source:
DateHeadline
Arbutus Biopharma (NASDAQ:ABUS) Coverage Initiated at Robert W. BairdArbutus Biopharma (NASDAQ:ABUS) Coverage Initiated at Robert W. Baird
www.americanbankingnews.com - February 19 at 5:12 PM
FY2019 Earnings Estimate for Arbutus Biopharma Corp Issued By Wedbush (NASDAQ:ABUS)FY2019 Earnings Estimate for Arbutus Biopharma Corp Issued By Wedbush (NASDAQ:ABUS)
www.americanbankingnews.com - February 13 at 7:54 AM
Arbutus Biopharma Corp (NASDAQ:ABUS) to Post FY2024 Earnings of ($0.82) Per Share, Wedbush ForecastsArbutus Biopharma Corp (NASDAQ:ABUS) to Post FY2024 Earnings of ($0.82) Per Share, Wedbush Forecasts
www.americanbankingnews.com - February 12 at 7:56 AM
Arbutus Biopharma Corp (NASDAQ:ABUS) Sees Large Growth in Short InterestArbutus Biopharma Corp (NASDAQ:ABUS) Sees Large Growth in Short Interest
www.americanbankingnews.com - February 11 at 5:58 PM
B. Riley Reaffirms "Buy" Rating for Arbutus Biopharma (NASDAQ:ABUS)B. Riley Reaffirms "Buy" Rating for Arbutus Biopharma (NASDAQ:ABUS)
www.americanbankingnews.com - February 11 at 11:17 AM
Arbutus bails on AB-452; shares down 15% premarketArbutus bails on AB-452; shares down 15% premarket
seekingalpha.com - February 10 at 1:33 PM
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-DestabilizerArbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
finance.yahoo.com - February 10 at 1:33 PM
Arbutus Biopharma Corp (NASDAQ:ABUS) Receives Consensus Rating of "Hold" from AnalystsArbutus Biopharma Corp (NASDAQ:ABUS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 10 at 8:53 AM
Arbutus Biopharma (NASDAQ:ABUS) Lifted to Outperform at JMP SecuritiesArbutus Biopharma (NASDAQ:ABUS) Lifted to Outperform at JMP Securities
www.americanbankingnews.com - February 5 at 9:37 AM
Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) StockOptions Traders Expect Huge Moves in Arbutus Biopharma (ABUS) Stock
finance.yahoo.com - December 30 at 2:57 PM
Arbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See ModeArbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See Mode
finance.yahoo.com - December 19 at 5:52 PM
Arbutus Biopharma EPS misses by $1.26, misses on revenueArbutus Biopharma EPS misses by $1.26, misses on revenue
seekingalpha.com - November 6 at 12:49 PM
Arbutus Biopharma Corporations (ABUS) CEO Bill Collier on Q3 2019 Results - Earnings Call TranscriptArbutus Biopharma Corporation's (ABUS) CEO Bill Collier on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 6 at 12:49 PM
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue EstimatesArbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 6 at 12:49 PM
Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateArbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - November 6 at 7:48 AM
Were A Little Worried About Arbutus Biopharmas (NASDAQ:ABUS) Cash Burn RateWe're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
finance.yahoo.com - November 3 at 2:30 PM
We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn RateWe're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate
finance.yahoo.com - November 3 at 9:29 AM
Arbutus to Report Third Quarter 2019 Financial ResultsArbutus to Report Third Quarter 2019 Financial Results
finance.yahoo.com - October 30 at 12:26 PM
Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should KnowWill Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know
finance.yahoo.com - October 30 at 12:26 PM
Bucks biopharm firm halts study of potential hepatitis B cureBucks biopharm firm halts study of potential hepatitis B cure
finance.yahoo.com - October 10 at 6:28 PM
Arbutus Biopharma -28% after stopping development of hepatitis B drugArbutus Biopharma -28% after stopping development of hepatitis B drug
seekingalpha.com - October 4 at 4:08 PM
Arbutus -24.5% as it discontinues hepatitis treatmentArbutus -24.5% as it discontinues hepatitis treatment
seekingalpha.com - October 3 at 10:06 PM
Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis BArbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B
finance.yahoo.com - October 3 at 5:05 PM
Did You Manage To Avoid Arbutus Biopharmas (NASDAQ:ABUS) Devastating 93% Share Price Drop?Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop?
finance.yahoo.com - September 19 at 10:43 AM
Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop?Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop?
finance.yahoo.com - September 19 at 10:43 AM
Arbutus on the hook for $5.8M in UBC patent caseArbutus on the hook for $5.8M in UBC patent case
seekingalpha.com - August 26 at 7:45 PM
Arbutus to Participate at Wedbush PacGrow Healthcare ConferenceArbutus to Participate at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 6 at 9:06 AM
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call TranscriptArbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 5 at 11:40 PM
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue EstimatesArbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 5 at 11:40 PM
Arbutus Biopharma EPS misses by $0.08, misses on revenueArbutus Biopharma EPS misses by $0.08, misses on revenue
seekingalpha.com - August 5 at 9:07 AM
Arbutus Bio misses Q1 consensusArbutus Bio misses Q1 consensus
seekingalpha.com - August 5 at 9:07 AM
Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateArbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - August 5 at 9:07 AM
Arbutus to Report Second Quarter 2019 Financial ResultsArbutus to Report Second Quarter 2019 Financial Results
finance.yahoo.com - July 29 at 11:19 AM
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should KnowWill Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - July 26 at 8:30 AM
Arbutus up 3% after hours on encouraging data on HBV candidate AB-506Arbutus up 3% after hours on encouraging data on HBV candidate AB-506
seekingalpha.com - July 15 at 6:59 PM
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis BArbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
finance.yahoo.com - July 15 at 6:59 PM
Here’s What Hedge Funds Think About Arbutus Biopharma Corp (ABUS)Here’s What Hedge Funds Think About Arbutus Biopharma Corp (ABUS)
finance.yahoo.com - July 4 at 6:56 PM
Arbutus sells portion of Onpattro royalties to Canadian pension planArbutus sells portion of Onpattro royalties to Canadian pension plan
seekingalpha.com - July 2 at 6:40 PM
Arbutus receives clearance to initiate early-stage AB-729 trial; shares up 8% premarketArbutus receives clearance to initiate early-stage AB-729 trial; shares up 8% premarket
seekingalpha.com - June 20 at 7:51 PM
Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
finance.yahoo.com - June 20 at 7:58 AM
New President & CEO at Arbutus BioNew President & CEO at Arbutus Bio
seekingalpha.com - June 17 at 8:34 AM
Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
finance.yahoo.com - June 17 at 8:34 AM
Arbutus to Participate at JMP Securities Life Sciences ConferenceArbutus to Participate at JMP Securities Life Sciences Conference
finance.yahoo.com - June 13 at 12:58 PM
Arbutus Biopharma (ABUS) Presents At UBS Global Healthcare Conference - SlideshowArbutus Biopharma (ABUS) Presents At UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 23 at 7:26 PM
Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO?Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO?
finance.yahoo.com - May 22 at 7:18 PM
Arbutus to Present at Upcoming May 2019 ConferencesArbutus to Present at Upcoming May 2019 Conferences
finance.yahoo.com - May 13 at 7:55 PM
Arbutus Biopharma Corporation (ABUS) CEO Mark Murray on Q1 2019 Results - Earnings Call TranscriptArbutus Biopharma Corporation (ABUS) CEO Mark Murray on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 8:24 AM
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate UpdateArbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
www.globenewswire.com - May 6 at 7:40 PM
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue EstimatesArbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 6 at 7:40 PM
Arbutus to Report First Quarter 2019 Financial ResultsArbutus to Report First Quarter 2019 Financial Results
finance.yahoo.com - April 29 at 6:43 PM
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel